Pomanda estimates the enterprise value of N & G PHARMA LIMITED at £2.5m based on a Turnover of £5.2m and 0.48x industry multiple (adjusted for size and gross margin).
n & g pharma limitedEstimated Valuation
£674k
Pomanda estimates the enterprise value of N & G PHARMA LIMITED at £674k based on an EBITDA of £151.7k and a 4.44x industry multiple (adjusted for size and gross margin).
n & g pharma limitedEstimated Valuation
£1m
Pomanda estimates the enterprise value of N & G PHARMA LIMITED at £1m based on Net Assets of £535.2k and 1.89x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
N & G Pharma LimitedOverview
N & G Pharma Limited is a live company located in stourbridge, DY8 1EP with a Companies House number of 09099448. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in June 2014, it's largest shareholder is
mrs ravinder bhandal
with a 50% stake. N & G Pharma Limited is a established,
mid sized company, Pomanda has estimated its turnover at
£5.2m with
rapid
growth in recent years.
Pomanda's financial health check has awarded N & G Pharma Limited a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 6 areas for improvement. Company Health Check FAQs
Health Rating2.5out of 5
2 Strong
3 Regular
6 Weak
Size
annual sales of £5.2m, make it smaller than the average company (£25.4m)
£5.2m - N & G Pharma Limited
£25.4m - Industry AVG
Growth
3 year (CAGR) sales growth of 33%, show it is growing at a faster rate (5.5%)
33% - N & G Pharma Limited
5.5% - Industry AVG
Production
with a gross margin of 27.8%, this company has a comparable cost of product (27.8%)
27.8% - N & G Pharma Limited
27.8% - Industry AVG
Profitability
an operating margin of 2.8% make it less profitable than the average company (4%)
2.8% - N & G Pharma Limited
4% - Industry AVG
Employees
with 3 employees, this is below the industry average (37)
3 - N & G Pharma Limited
37 - Industry AVG
Pay Structure
on an average salary of £78.1k, the company has an equivalent pay structure (£78.1k)
£78.1k - N & G Pharma Limited
£78.1k - Industry AVG
Efficiency
resulting in sales per employee of £1.7m, this is more efficient (£643.4k)
£1.7m - N & G Pharma Limited
£643.4k - Industry AVG
Debtor Days
it gets paid by customers after 94 days, this is later than average (57 days)
94 days - N & G Pharma Limited
57 days - Industry AVG
Creditor Days
its suppliers are paid after 28 days, this is close to average (29 days)
28 days - N & G Pharma Limited
29 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - N & G Pharma Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 0 weeks, this is less cash available to meet short term requirements (11 weeks)
0 weeks - N & G Pharma Limited
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 67.1%, this is a higher level of debt than the average (52.4%)
67.1% - N & G Pharma Limited
52.4% - Industry AVG
N & G PHARMA LIMITED financials
EXPORT
N & G Pharma Limited's latest turnover from June 2024 is estimated at £5.2 million and the company has net assets of £535.2 thousand. According to their latest financial statements, N & G Pharma Limited has 3 employees and maintains cash reserves of £4.4 thousand as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Jun 2024
Jun 2023
Jun 2022
Jun 2021
Jun 2020
Jun 2019
Jun 2018
Jun 2017
Jun 2016
Jun 2015
Turnover
5,213,580
5,198,996
4,528,533
2,215,515
599,015
65,317
1,838,869
2,585,160
2,560,691
4,018,372
Other Income Or Grants
Cost Of Sales
3,766,226
3,774,318
3,339,102
1,672,013
438,522
47,978
1,341,683
1,894,887
1,864,255
2,911,716
Gross Profit
1,447,354
1,424,678
1,189,431
543,502
160,493
17,339
497,186
690,273
696,436
1,106,656
Admin Expenses
1,302,832
1,219,909
929,925
444,811
170,824
28,468
835,440
527,536
404,664
1,130,365
Operating Profit
144,522
204,769
259,506
98,691
-10,331
-11,129
-338,254
162,737
291,772
-23,709
Interest Payable
Interest Receivable
350
403
154
10
2
30
140
70
150
134
Pre-Tax Profit
144,872
205,172
259,659
98,701
-10,329
-11,099
-338,114
162,806
291,923
-23,575
Tax
-36,218
-51,293
-49,335
-18,753
-30,933
-58,384
Profit After Tax
108,654
153,879
210,324
79,948
-10,329
-11,099
-338,114
131,873
233,538
-23,575
Dividends Paid
Retained Profit
108,654
153,879
210,324
79,948
-10,329
-11,099
-338,114
131,873
233,538
-23,575
Employee Costs
234,155
230,517
208,338
264,899
124,969
62,795
62,219
289,061
236,975
350,629
Number Of Employees
3
3
3
4
2
1
1
5
5
8
EBITDA*
151,716
211,738
264,028
100,403
-8,624
-10,144
-337,095
164,101
293,376
-22,996
* Earnings Before Interest, Tax, Depreciation and Amortisation
Jun 2024
Jun 2023
Jun 2022
Jun 2021
Jun 2020
Jun 2019
Jun 2018
Jun 2017
Jun 2016
Jun 2015
Tangible Assets
29,569
35,264
42,233
6,526
7,486
5,583
6,568
7,727
9,091
10,695
Intangible Assets
Investments & Other
Debtors (Due After 1 year)
Total Fixed Assets
29,569
35,264
42,233
6,526
7,486
5,583
6,568
7,727
9,091
10,695
Stock & work in progress
267,745
249,435
80,555
62,946
74,802
165,802
344,619
Trade Debtors
1,355,572
1,398,990
1,058,528
277,821
425,998
600,360
471,871
460,633
Group Debtors
Misc Debtors
237,107
6,845
3,800
3,800
22,391
4,479
18,699
Cash
4,368
8,981
7,136
17,432
3,422
1,070
6,829
49,020
6,620
53,516
misc current assets
total current assets
1,597,047
1,414,816
1,337,209
548,488
106,368
5,549
514,472
724,182
644,293
858,768
total assets
1,626,616
1,450,080
1,379,442
555,014
113,854
11,132
521,040
731,909
653,384
869,463
Bank overdraft
Bank loan
Trade Creditors
290,848
249,933
695,316
447,440
104,964
8,081
398,337
389,973
443,321
892,938
Group/Directors Accounts
other short term finances
hp & lease commitments
other current liabilities
793,176
764,786
403,436
43,810
25,074
10,328
118,881
total current liabilities
1,084,024
1,014,719
1,098,752
491,250
130,038
18,409
517,218
389,973
443,321
892,938
loans
hp & lease commitments
Accruals and Deferred Income
other liabilities
provisions
7,393
8,816
8,024
1,422
1,422
total long term liabilities
7,393
8,816
8,024
1,422
1,422
total liabilities
1,091,417
1,023,535
1,106,776
492,672
131,460
18,409
517,218
389,973
443,321
892,938
net assets
535,199
426,545
272,666
62,342
-17,606
-7,277
3,822
341,936
210,063
-23,475
total shareholders funds
535,199
426,545
272,666
62,342
-17,606
-7,277
3,822
341,936
210,063
-23,475
Jun 2024
Jun 2023
Jun 2022
Jun 2021
Jun 2020
Jun 2019
Jun 2018
Jun 2017
Jun 2016
Jun 2015
Operating Activities
Operating Profit
144,522
204,769
259,506
98,691
-10,331
-11,129
-338,254
162,737
291,772
-23,709
Depreciation
7,194
6,969
4,522
1,712
1,707
985
1,159
1,364
1,604
713
Amortisation
Tax
-36,218
-51,293
-49,335
-18,753
-30,933
-58,384
Stock
-267,745
18,310
168,880
80,555
-62,946
-11,856
-91,000
-178,817
344,619
Debtors
186,844
343,507
780,707
259,230
17,912
-440,218
-155,663
128,489
11,238
460,633
Creditors
40,915
-445,383
247,876
342,476
96,883
-390,256
8,364
-53,348
-449,617
892,938
Accruals and Deferred Income
28,390
361,350
359,626
18,736
14,746
-108,553
118,881
Deferred Taxes & Provisions
-1,423
792
6,602
1,422
Cash flow from operations
-3,464
1,442
29,780
14,752
5,960
-5,789
-42,331
42,331
-47,046
64,690
Investing Activities
capital expenditure
-1,499
-40,229
-752
-3,610
-11,408
Change in Investments
cash flow from investments
-1,499
-40,229
-752
-3,610
-11,408
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
Hire Purchase and Lease Commitments
other long term liabilities
share issue
100
interest
350
403
154
10
2
30
140
70
150
134
cash flow from financing
350
403
154
10
2
30
140
70
150
234
cash and cash equivalents
cash
-4,613
1,845
-10,296
14,010
2,352
-5,759
-42,191
42,400
-46,896
53,516
overdraft
change in cash
-4,613
1,845
-10,296
14,010
2,352
-5,759
-42,191
42,400
-46,896
53,516
n & g pharma limited Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for n & g pharma limited. Get real-time insights into n & g pharma limited's credit score, group structure and payment trends.
Perform a competitor analysis for n & g pharma limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mid companies, companies in DY8 area or any other competitors across 12 key performance metrics.
n & g pharma limited Ownership
N & G PHARMA LIMITED group structure
N & G Pharma Limited has no subsidiary companies.
Ultimate parent company
N & G PHARMA LIMITED
09099448
N & G PHARMA LIMITED Shareholders
The largest shareholders in N & G Pharma Limited include Mrs Ravinder Bhandal and Charnjit Singh Bhandal.
mrs ravinder bhandal
50%
charnjit singh bhandal
50%
n & g pharma limited directors
N & G Pharma Limited currently has 2 directors.
The longest serving directors include
Mr Peter Sidaway (Jun 2014) and
Mr Charnjit Bhandal (Jan 2019).
suite 2 the old bank, 2 coventry street, stourbridge, west midlands, DY8 1EP
Bank
-
Legal Advisor
-
n & g pharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to n & g pharma limited. Currently there are 1 open charges and 0 have been satisfied in the past.
n & g pharma limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for N & G PHARMA LIMITED. This can take several minutes, an email will notify you when this has completed.
n & g pharma limitedCompanies House Filings - See Documents
